ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Ocular Therapeutix Inc

Ocular Therapeutix Inc (OCUL)

6.25
0.17
(2.80%)
Closed June 23 4:00PM
6.25
0.00
(0.00%)
After Hours: 6:53PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
6.25
Bid
6.18
Ask
6.27
Volume
6,988,401
5.96 Day's Range 6.26
1.995 52 Week Range 11.31
Market Cap
Previous Close
6.08
Open
6.06
Last Trade Time
Financial Volume
$ 42,577,830
VWAP
6.0926
Average Volume (3m)
2,528,035
Shares Outstanding
154,888,915
Dividend Yield
-
PE Ratio
-11.99
Earnings Per Share (EPS)
-0.52
Revenue
58.44M
Net Profit
-80.74M

About Ocular Therapeutix Inc

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitation... Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Ocular Therapeutix Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker OCUL. The last closing price for Ocular Therapeutix was $6.08. Over the last year, Ocular Therapeutix shares have traded in a share price range of $ 1.995 to $ 11.31.

Ocular Therapeutix currently has 154,888,915 shares outstanding. The market capitalization of Ocular Therapeutix is $968.06 million. Ocular Therapeutix has a price to earnings ratio (PE ratio) of -11.99.

OCUL Latest News

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of...

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD...

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.121.3592233015.156.4455.1138212935.77342759CS
40.427.204116638085.836.4454.7923232875.53073177CS
12-2.85-31.31868131879.19.10124.0625280355.82973117CS
262.1452.06812652074.1111.313.759922514206.76142246CS
521.634.40860215054.6511.311.99516033035.79534659CS
156-7.32-53.942520265313.5714.771.99511462266.01535616CS
2601.9244.34180138574.3324.31.99510581227.6328901CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

OCUL Discussion

View Posts
Whalatane Whalatane 3 months ago
OCUL. P2 data 4/5/24
REUTERS
10:03 AM ET 04/06/2024
April 6 (Reuters) - Ocular Therapeutix Inc (OCUL):
* OCULAR THERAPEUTIX™ ANNOUNCES POSITIVE PHASE 2 PAXTRAVA™ GLAUCOMA DATA AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024 ANNUAL MEETING
* OCULAR THERAPEUTIX INC (OCUL) - GENERALLY WELL TOLERATED WITH NO IMPACT ON CORNEAL HEALTH OBSERVED
* OCULAR THERAPEUTIX INC (OCUL) - CLINICALLY MEANINGFUL MEAN IOP REDUCTION OF ABOUT 24-30% FROM BASELINE OBSERVED OVER SIX MONTHS Source text for Eikon: Further company coverage:

Kiwi
👍️0
Monksdream Monksdream 3 months ago
OCUL under $10
👍️0
Monksdream Monksdream 3 months ago
OCUL 10Q due March 11
👍️0
glenn1919 glenn1919 6 months ago
OCUL....................................https://stockcharts.com/h-sc/ui?s=OCUL&p=W&b=5&g=0&id=p86431144783
👍️0
trendzone trendzone 1 year ago
Tard sells $6.00 call option at $0.15 at the close,apparently they were born yesterday.
👍️0
glenn1919 glenn1919 1 year ago
OCUL..........................................https://stockcharts.com/h-sc/ui?s=OCUL&p=W&b=5&g=0&id=p86431144783
👍️0
trendzone trendzone 1 year ago
Clueless fool sells $6.00 call option at $0.10 when they were just trading at $0.30,with the big rally going on in the stock today, what a total fool they are.
👍️0
cuggegrosse cuggegrosse 1 year ago
I chose OCUL to invest in because the market conditions should not effect the PPS(much),plus I can sell covered calls and make some monthly cash,besides they have products that are in demand !!!!
👍️ 1
cuggegrosse cuggegrosse 1 year ago
Yes I have noticed that
👍️ 1
Tzr250rg Tzr250rg 1 year ago
Ask is super thin wont take much to move. GLTUA
👍️0
cuggegrosse cuggegrosse 1 year ago
My eye doctor says Dextenza is a very good drug and he raccomends it !!!!!
👍️ 1
cuggegrosse cuggegrosse 1 year ago
DEXTENZA is doing very,very well,great revs expected in 2023
👍️ 1
cuggegrosse cuggegrosse 1 year ago
This company could go to $8.00 very eassy
👍️ 1
spotonge spotonge 2 years ago
boys need to wake up
👍️0
biotechslayr biotechslayr 2 years ago
Is anyone at all following OCUL into the end of the months binary? TKI data could be a game changer. Total TAM is ridiculous (look at REGN mcap!)
👍️ 1
oxnous oxnous 3 years ago
OCUL --charting


👍️0
oxnous oxnous 3 years ago
With the aging population, eye care is becoming an increasing concern. Dry eye, glaucoma, macular degeneration etc. will be expanding market sub sectors
👍️0
ClayTrader ClayTrader 3 years ago
* * $OCUL Video Chart 04-29-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 4 years ago
Just In: $OCUL Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that its application for the creation of a Category I Current Procedural Ter...

In case you are interested OCUL - Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts
👍️0
whytestocks whytestocks 4 years ago
Breaking News: $OCUL Ocular Therapeutix(TM) Announces Topline Phase 1 Clinical Trial Results of OTX-CSI

OTX-CSI demonstrates improvement in signs and symptoms of Dry Eye Disease Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the ey...

Got this from OCUL - Ocular Therapeutix(TM) Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
👍️0
TheFinalCD TheFinalCD 4 years ago
OCUL 10.87 NEW HIGH OF DAY
👍️0
whytestocks whytestocks 4 years ago
Just In: $OCUL Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported preliminary, unaudited net product revenue for the third quarter ended Septe...

Find out more OCUL - Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter
👍️0
now invest now invest 4 years ago
Thus far OCUL is trading nicely!!
👍️0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 05-22-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 03-04-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
edwardport edwardport 4 years ago
near term 10% projected increase in market price

closed on 2/7/20 @ $5.21
👍️0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 02-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 4 years ago
* * $OCUL Video Chart 01-03-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 11-29-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
TFMG TFMG 5 years ago
OCUL - POSSIBLE 25% TREND MOVE ON THE DAILY

Ocular Therapeutix , Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

SHORT INTEREST
8.24M 07/15/19

P/E Current
-2.78

P/E Ratio (with extraordinary items)
-2.92

Average Recommendation: OVERWEIGHT

Average Target Price: 9.67

👍️0
tste9 tste9 5 years ago
Great news! BUT, hoped for more volume price etc. wow
GLA
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 07-26-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a ...

Got this from Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
👍️0
smallbio smallbio 5 years ago

Is DEXTENZA currently only targeting medicare patients, as there is no private insurance company will reimburse the cost?
👍️0
tste9 tste9 5 years ago
What is up with this little piggy, lately! #&*#@*
👍️0
tste9 tste9 5 years ago
Great news thanks for post. Do you know of any web site that posts OCUL sales per week. Thank you. GL
👍️0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Commercial Launch of DEXTENZA® (dexamethasone intracanalicular insert) 0.4 mg for Ophthalmic Use in the United States

Pass-through payment status and C-code from the Centers for Medicare and Medicaid Services (CMS) now active Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and ...

In case you are interested https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-commercial-launch-of-dextenza-x-8439742.html
👍️0
swingingRichard swingingRichard 5 years ago
Shorted 10,000 shares. Looking good.
👍️0
tste9 tste9 5 years ago
Shorts ease out as usual. criminal how shorts manipulate SP then just slither out unharmed. GLA
👍️0
tste9 tste9 5 years ago
YEA BABY!
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 06-21-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

DEXTENZA ® Now Approved for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

Find out more https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-fda-approval-of-supplemental-new-drug-application-snda-for-dextenza-xae-0-4-dexamethasone-intracanalicular-insert-for-ophthalmic-use-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery-8394606.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 06-11-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Tzr250rg Tzr250rg 5 years ago
low volume today
👍️0
whytestocks whytestocks 5 years ago
News: $OCUL Ocular Therapeutix(TM) Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved t...

Got this from https://marketwirenews.com/news-releases/ocular-therapeutix-tm-announces-receipt-of-c-code-and-pass-through-payment-status-for-dextenza-xae--8261962.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $OCUL Video Chart 05-21-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
now invest now invest 5 years ago
Stopped in to see anything up.... oh well...
👍️0
RolandDoe RolandDoe 5 years ago
Hardly
👍️0
Rakbors Rakbors 5 years ago
No
👍️0
RickieK RickieK 5 years ago
Hellooooo is there anyone here
👍️0

Your Recent History

Delayed Upgrade Clock